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Peyronie’s disease (PD) is a benign fibroproliferative disorder, which causes the formation of 
plaque in the tunica albuginea of the corpora cavernosa in the penis. The disease is named 
after François Gigot de la Peyronie (1678-1747), although Fallopius and Vesalius had 
already described the disorder in 1561 (1). 
Since the time of Peyronie, who sent his patients to the holy water of Baragès in the French 
Pyrenees (2), many nonsurgical empirical approaches have been tried in an attempt to cure 
PD, but there is still no effective cure. This is mainly due to a lack of understanding 
concerning the biology and pathology of PD (3). Once a calcified or even ossified plaque has 
developed, there is no nonsurgical treatment to make it disappear.  
In 2004, Ralph and Minhas found 38 nonsurgical treatments of PD (4). At the time of writing, 
none of them has received a grade A recommendation under the American and European 
guidelines (5, 6). Collagenase from Clostridium histolyticum is the only drug approved by the 
US Food and Drug Administration and the European Medicines Agency for intralesional 
injection in patients with palpable plaque and dorsal or dorsolateral curvature greater than 
30°, smaller than 90° and intact erectile function.  
In the acute phase, PD is treated conservatively (non-steroidal anti-inflammatory 
medications may offer analgesia) and, in general, surgical approaches are only attempted 
after around one year in patients for whom the disease has not worsened for at least three 
months and who have a curvature that impedes sexual intercourse. During that waiting time, 
patients are often willing to undergo treatments. The effectiveness of these treatments, 
however, has not been proven in a three-arm study design (test treatment vs placebo vs no 
treatment) with an 18-month duration. In this article, we reflect on the past, present and 

















Material and methods 
An extensive literature search (The Cochrane Library, PubMed/MEDLINE, Web of Science, 
EMBASE and old German, Dutch, French and English medical books on male sexual 
functioning) was performed with the searches spanning until January 2018. The search 
included all medical interventions in patients with PD (or ‘cavernosits’, ‘penile fibrosis’, 
‘fibrous sclerosis of the penis’, ‘induratio penis plastica’ or ‘Van Buren’s disease’), as 
reported in articles in any of the previously mentioned databases, or others found as 
references in articles and antiquarian books. We discuss our overall findings. 
 
Results 
In all consulted databases and references, researchers found a total of 48 nonsurgical 
interventions in articles published from 1743 to 2017. These included eleven external, 
eleven intralesional, seven topical and 23 oral interventions (Table 1). A further four of the 
treatments comprised a combination of two of the nonsurgical interventions. 
Table 1. Historical overview of first reports about nonsurgical interventions for 
PD  
(E = external; I = intralesional; O = Oral; T = topical)  
Year Therapy O/T/I/E Authors 
1743 Mercury and mineral water O De la Peyronie (2) 
1840 Potassium iodide O/T Ricord (7)* 
1864 Electricity E Van Buren (8)* 
1876 
1878 
Bromides and hyperthermia 
Mercury and iodides 
O/E 
O/T 
Hodgen (9)*  
Curling (10) 
1890 Sulfur O Dubuc (11)* 
1896 Copper sulfate O O’Zoux (12)* 
1901 
1901 
Salicylate and thiosinamin 





1902 Arsenic O Reliquet (15)* 
1907 Fibrinolysin O/T Waelsch (16)* 
1910 Ionization E Lavenant: quoted by Zislin (17)* 















1911 X-radiation E Bernasconi (19)* 
1912 Ultraviolet light E LeFur (20)* 
1922 Trypsin  I Sonntag (21)* 









1949 Vitamin E O Scardino (24) 
1954 Cortisone  I Teasly (25) 
1954 
1955 








O Zarafonetis (28) 
1960 Histamine iontophoresis T Whalen (29) 
1963 Prednisolone O Chesney (30) 
1967 Ultrasound E Heslop (31) 
1967 Dimethyl sulfoxide  O Persky (32) 
1967 Steroid iontophoresis T Rothfeld (33) 
1970 Procarbazine O Aboulker (34) 
1975 Parathyroid hormone  I Morales (35) 
1981 Orgoteine I Bartsch (36) 
1983 Βeta-aminopropionitrile T Gelbard (37) 
1985 Collagenase  I Gelbard (38) 
1985 Laser  E Puente de la Vega (39) 
1988 Prostacyclin I Strachan (40) 
1989 Lithotrypsy E Bellorofonte (41) 
1991 Interferon I Benson (42) 
1992 Tamoxifen O Ralph (43) 
1994 Verapamil I Levine (44) 
1994 Colchicine O Akkus (45) 
2001 Carnitine O Biagiotti (46) 
2001 Traction devices E Scroppo (47) 






Omega-3 fatty acids 
Nicardipine 
Superoxide-dismutase 









*Cited in (53) 
Discussion 
Nowadays, surgery is of minimal value in patients with peptic duodenal ulcers, pulmonary 
tuberculosis or anus carcinoma. For those disorders, effective nonsurgical treatments have 















Throughout the past three centuries, many medical treatments have been tried, but nearly all 
were reported after clinical studies with a low number of patients and/or based on anecdotal 
experiences. In 1968, for example, Aron noted a regression of Dupuytren’s disease in a 
patient who was treated with the cytotoxic procarbazine for Hodgkin’s disease, and he 
suggested the use of this drug in fibroproliferative disorders (54). In the 1970s, investigators 
from France reported excellent results in patients with PD, but in Belgium, procarbazine had 
disappointing results (55, 56). It is interesting to note that many titles of the articles on PD 
treatments used the words ‘new therapy’. 
The modern era of trial and error in the medical therapy of PD began in 1949 with Scardino’s 
report on the use of tocopherols (24). Teasly first reported successful intralesional 
corticosteroid injections in 1954 (25). However, because a widely accepted and effective 
medical treatment for PD was unavailable, research was primarily done by surgically-
orientated urologists. They understandably focused on operation techniques, which led to 
them neglecting the pursuit of medical therapies. The only exceptions were the collagenase 
protocols of 1993 and the collagenase clostridium histolyticum (CCH) injection therapy in the 
last decade. Collagenase was the only subject of study in which the effects were evaluated 
in a randomized, placebo-controlled, double-blind manner. Moreover, this was preceded by 
animal studies (57). One of the few other animal studies showed a reduction of fibrosis in the 
tunica albuginea when the rats consumed pentoxifylline, L-arginine or any of three PDE-5 
inhibitors (sildenafil, vardenafil, tadalafil) through drinking water (48). The authors 
hypothesized that the increase in NO and/or cGMP/cAMP levels by chronic administration of 
nitrergic agents or PDE inhibitors could be effective in reversing the fibrosis of PD and, more 
speculatively, other fibrotic conditions. 
In the American and European guidelines, none of the options depicted in the table carries a 
grade A recommendation. Today, drugs such as carnitine, arginine and dimethyl sulfoxide 
(DMSO) belong to the domain of complementary and alternative medicine (CAM) in most 















which is the crude extract of pineapple and has fibrinolytic, antithrombotic and anti-
inflammatory properties (58). However, there are no scientific data about its use by PD 
patients. According to the National Center for Complementary and Integrative Health in the 
US, bromelain is available as a powder, cream, tablet and capsule.  
Overall, oral medical treatments are considered potentially effective in only the early phase 
of PD, that is, before plaque hardening and calcification occur. According to the current 
European guidelines, oral steroids, vitamin E and tamoxifen should be avoided completely 
as treatment. The American Urological Association (AUA) added procarbazine, omega-3 
fatty acids and the combination of L-carnitine with vitamin E to their list of treatments to 
avoid. The remaining drugs for off-label use are pentoxifylline, a PDE-5-inhibitor and/or 
arginine, or a combination of these. The AUA guidelines from 2015 report that pentoxifylline 
(whether or not combined with intralesional verapamil and traction) can reduce pain and ED 
(6).   
Since the release of the 2015 AUA guidelines, an Italian study showed that treatment that 
combined pentoxifylline with minor antioxidants (propolis, blueberries and vitamin E) and 
topical diclofenac was effective in patients with early-stage PD (59). This study also 
demonstrated that the clinical efficacy of pentoxyphyline was greater when administered 
both orally and locally through perilesional injection. 
 
Current knowledge and new drugs for fibrosis  
In all fibroproliferative diseases, the differentiation and activation of myofibroblasts is one of 
the most important processes. These cells are the main producers of collagen and other 
extracellular matrix components. They also contain α-actin, which is a protein that causes 
cell contraction and thus contributes to distortion and dysfunction (60). Myofibroblasts 
originate from locally-present fibroblasts or differentiated infiltrating fibrocytes (61). 















cells to myofibroblasts is influenced by various growth factors, cytokines and clotting factors. 
As the healing process progresses, the myofibroblasts will eventually disappear by 
apoptosis. It has been hypothesized that deregulation of this apoptotic process can occur, 
thus allowing more myofibroblasts to remain active (62). Addtionally, there are indications 
that epigenetic changes in fibroblasts or myofibroblasts may contribute to fibrotic changes 
(63, 64). Nowadays, as in PD, there are largely ineffective therapeutic options for patients 
with fibrotic diseases in general. New agents under investigation are pirfenidone, tyrosine 
kinase inhibitors, transforming growth factor-β, platelet-derived growth factor, interleukin-13 
and lysyl oxidase-2 (65).  
Pirfenidone is an expensive, small molecule that is available for oral use. The exact 
molecular mechanism of action is not completely explained. Based on in vitro studies, it is 
assumed that pirfenidone inhibits the proliferation and synthesis of pro-fibrotic and 
inflammatory mediators, and the collagen synthesis by fibroblasts and myofibroblasts. It is 
the first specific anti-fibrotic agent that is approved for the treatment of patients with 
idiopathic pulmonary fibrosis in Europe, Japan and the United States (66). New studies 
could show whether pirfenidone works in patients with fibrotic diseases other than idiopathic 
pulmonary fibrosis. 
The protein tyrosine kinase inhibitor nintedanib seems to be successful in the treatment of 
patients with pulmonary fibrosis, while some forms of systemic sclerosis seem to decrease 
after treatment with the protein tyrosine kinase inhibitor imatinib mesylate (67, 68). These 
new treatment options, however, are not yet beyond phase II studies in patients with 
idiopathic pulmonary fibrosis. It remains to be seen whether these therapies can also be 

















Many of the old and new drugs reviewed have a reasonable basis for their use, but the lack 
of basic research on the biology and pathology of PD makes it difficult to understand the 
working mechanisms. The most important goal of medical therapy is to prevent or halt the 
process of plaque formation and scarring. Patients typically present pain during the acute 
phase. If the plaque begins to harden, oral drugs will not be delivered. This is most likely due 
to the decreased vasculature. Therefore, pharmacotherapy should be initiated as soon as 
possible in the acute phase of PD.   
Nowadays, patients may use pentoxifylline, a PDE-5-inhibitor, antioxidants or a combination 
of these off-label. Antioxidants belong to the domain of complementary and alternative 
medicine.  
The search for new, well-tolerated and effective medical therapy has to continue. In the end, 
the management of PD should improve, with fewer patients needing surgery. In that respect, 
we strongly recommend close collaboration with nonsurgical experts in fibrotic diseases.  
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